Patent Granted for Treating Rheumatoid Arthritis

A US patent has been awarded to MorphoSys AG of Martinsried, Germany, and the University of Melbourne in Australia for use of antibodies against granulocyte-macrophage colony-stimulating factor. In 2007, the university granted MorphoSys an exclusive license for the patent family. The US patent will be used to treat the inflammation of rheumatoid arthritis by administering an antibody to patients that is directed against granulocyte-macrophage colony-stimulating factor.